Investigational Drug Information for SGS-742
✉ Email this page to a colleague
What is the drug development status for SGS-742?
SGS-742 is an investigational drug.
There have been 4 clinical trials for SGS-742.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2019.
The most common disease conditions in clinical trials are Sjogren's Syndrome, Amino Acid Metabolism, Inborn Errors, and Sclerosis. The leading clinical trial sponsors are University of Campania "Luigi Vanvitelli", University of Milan, and University of Modena and Reggio Emilia.
There are forty-two US patents protecting this investigational drug and four hundred and sixty-five international patents.
Summary for SGS-742
| US Patents | 42 |
| International Patents | 465 |
| US Patent Applications | 157 |
| WIPO Patent Applications | 86 |
| Japanese Patent Applications | 52 |
| Clinical Trial Progress | Phase 2 (2019-04-10) |
| Vendors | 24 |
Recent Clinical Trials for SGS-742
| Title | Sponsor | Phase |
|---|---|---|
| A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients | Peking Union Medical College Hospital | Phase 1/Phase 2 |
| Colchicine for Amyotrophic Lateral Sclerosis | Catholic University of the Sacred Heart | Phase 2 |
| Colchicine for Amyotrophic Lateral Sclerosis | IRCCS National Neurological Institute "C. Mondino" Foundation | Phase 2 |
Clinical Trial Summary for SGS-742
Top disease conditions for SGS-742
Top clinical trial sponsors for SGS-742
US Patents for SGS-742
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SGS-742 | See Plans and Pricing | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function | Pharnext (Paris, FR) | See Plans and Pricing |
| SGS-742 | See Plans and Pricing | Compositions for preventing and/or treating degenerative disorders of the central nervous system | Amicus Therapeutics, Inc. (Cranbury, NJ) | See Plans and Pricing |
| SGS-742 | See Plans and Pricing | Compositions and methods for neurological diseases | Coda Biotherapeutics, Inc. (South San Francisco, CA) | See Plans and Pricing |
| SGS-742 | See Plans and Pricing | Substituted propane-phosphinic acid compounds | Ciba-Geigy Corporation (Ardsley, NY) | See Plans and Pricing |
| SGS-742 | See Plans and Pricing | Substituted propane-phosphinic acid compounds | Ciba-Geigy Corporation (Ardsley, NY) | See Plans and Pricing |
| SGS-742 | See Plans and Pricing | Substituted propane-phosphinic acid compounds | Ciba-Geigy Corporation (Ardsley, NY) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SGS-742
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SGS-742 | Australia | AU2009242113 | 2028-04-29 | See Plans and Pricing |
| SGS-742 | Brazil | BRPI0911874 | 2028-04-29 | See Plans and Pricing |
| SGS-742 | Canada | CA2722295 | 2028-04-29 | See Plans and Pricing |
| SGS-742 | China | CN102065858 | 2028-04-29 | See Plans and Pricing |
| SGS-742 | China | CN104127434 | 2028-04-29 | See Plans and Pricing |
| SGS-742 | Eurasian Patent Organization | EA024147 | 2028-04-29 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
